je.st
news
Home
› Vertex Submits Supplemental New Drug Application (sNDA) To U.S. Food And Drug Administration For Use Of KALYDECO (ivacaftor) In People 18 And Older With Cystic Fibrosis Who Have The R117H Mutation
Vertex Submits Supplemental New Drug Application (sNDA) To U.S. Food And Drug Administration For Use Of KALYDECO (ivacaftor) In People 18 And Older With Cystic Fibrosis Who Have The R117H Mutation
2014-07-02 10:30:30| drugdiscoveryonline Home Page
Vertex Pharmaceuticals Incorporated recently announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the approval of KALYDECO in people with cystic fibrosis (CF) ages 18 and older who have the R117H mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
Tags: the
have
with
people
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||